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Objective To examine major congenital anomaly (CA) risks in
children of mothers with coeliac disease (CD) compared with
mothers without CD.
Design Population-based cohort study.
Setting Linked maternal–child medical records from a large
primary care database from the UK.
Population A total of 562 332 live singletons of mothers with and
without CD in 1990–2013.
Methods We calculated the absolute major CA risks in children
whose mothers had CD, and whether this was diagnosed or
undiagnosed before childbirth. Logistic regression with a
generalised estimating equation was used to estimate adjusted
odds ratios (aORs) with 95% confidence intervals (95% CIs) for
CAs associated with CD.
Main outcome measures Fourteen system-specific major CA
groups classified according to the European Surveillance of
Congenital Anomalies and neural tube defects (NTDs).
Results Major CA risk in 1880 children of mothers with CD was
293 per 10 000 liveborn singletons, similar to the risk in those
without CD (282; aOR 0.98, 95% CI 0.74–1.30). The risk was
slightly higher in 971 children, whose mothers were undiagnosed
(350; aOR 1.14, 95% CI 0.79–1.64), than in 909 children whose
mothers were diagnosed (231; aOR 0.80, 95% CI 0.52–1.24).
There was a three-fold increase in nervous system anomalies in
the children of mothers with undiagnosed CD (aOR 2.98, 95% CI
1.06–8.33, based on five exposed cases and one had an NTD), and
these women were all diagnosed with CD at least 4 years after
their children were born.
Conclusions There was no statistically significant increase in risk
of major CAs in children of mothers with coeliac disease overall,
compared with the general population.
Keywords Abnormalities, coeliac disease, congenital
epidemiology.
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Introduction
Coeliac disease (CD) is an autoimmune inflammatory dis-
ease of the small intestine, and the only treatment is life-
long avoidance of gluten. It is estimated to affect about 1%
of the population, based mainly on serology studies, in
both North America and Western Europe, with the major-
ity of patients not recognised clinically.1,2 CD is predomi-
nantly diagnosed in women and can potentially cause
health damage not only to the women themselves but also
to their offspring.3 It has been reported that women with
newly diagnosed CD have increased risks of unfavourable
pregnancy and fetal outcomes,4–9 such as miscarriage and
low-birthweight babies, which could possibly be prevented
by effective treatment, i.e. by gluten avoidance.5,7,9
The villous atrophy present in patients with CD can
cause malabsorption, anaemia, and micronutrient deficien-
cies, which could be a direct mechanism leading to any
adverse pregnancy and fetal outcomes.3 Previous research
has shown that micronutrient supplementation is beneficial
in reducing low birthweight and small-for-gestational-age
births.10 Folic acid deficiency is associated with neural tube
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Maternal medicine
defects (NTDs) and other congenital anomalies (CAs), and
a low level of folic acid has been reported in patients with
untreated CD.11,12 It has therefore been speculated that
women with CD may be more likely to give birth to
infants with CAs (particularly NTDs) compared with the
general population.12,13 Most previous studies in this area,
however, are small clinical studies where mothers having
children with various CAs have been screened for CD.13–16
To date, only three cohort studies have examined the
association between women with CD and the risk of CAs
in the general population.6,8,17 Although a Swedish study
found a small overall increased risk of CAs in children
born to women with undiagnosed CD,17 this increased risk
disappeared after restricting the analysis to children born
between 2000 and 2009. The two other studies showed no
increased risks; however, they were considerably under-
powered.6,8
In view of a lack of evidence in this area, we conducted
a population-based study to examine the risks of major CA
and specific anomalies in children born to women with
CD, compared with the general population. We also exam-
ined these in pregnant women with diagnosed and undiag-
nosed CD separately.
Methods
Study population
We included all singleton liveborn children of mothers
aged 15–45 years between January 1990 and January 2013
from The Health Improvement Network (THIN), where
anonymised medical records for both mothers and children
have been linked to provide prospectively recorded infor-
mation before, during, and after pregnancy. THIN is a
nationally representative database of computerised primary
care records, and covers nearly 6% of the UK population.18
THIN contains valid medical diagnoses, events, symptoms,
and drug prescriptions, and is widely used for pharmacoep-
idemiological studies.19
Mothers with CD were defined as those with a medical
Read code for a diagnosis of CD in their primary care
records, with or without a gluten-free prescription record
(including Read codes J690.00 CD, J690.13 gluten enterop-
athy, J690.14 sprue nontropical, J690100 acquired CD, and
J690z00 CD NOS). Each woman with CD was assigned a
date of diagnosis corresponding to the earliest date of her
first diagnostic record of CD or the date of her first record
of having a gluten-free prescription. We assessed the timing
of the CD diagnosis in relation to pregnancy and defined
mothers as having diagnosed CD if their first CD diagnosis
was recorded before childbirth. We defined women as hav-
ing undiagnosed CD if their first CD diagnosis was
recorded after childbirth. The comparison cohort consisted
of mothers without a medical diagnosis for CD in their
entire primary care records. Mothers with a diagnosis of
dermatitis herpetiformis or with a record of a gluten-free
prescription but with no diagnosis of CD were excluded,
representing only 0.1% and 0.8% of the initial study popu-
lation, respectively.
Defining major CA
We extracted all diagnostic recordings of major CAs from
the children’s general practice records and classified these
into system-specific groups by using Read codes corre-
sponding to the European Surveillance of Congenital
Anomalies classification,20 which is based on the Interna-
tional Classification of Disease (ICD–10). Children with
genetic anomalies or anomalies attributed to known terat-
ogens, e.g. anomalies resulting from maternal infections
and fetal alcohol syndrome, were excluded from the study
population, which represented only 0.1% of the study
population.
Defining other variables
We extracted maternal age at childbirth (considered as a
continuous variable) and calendar year of childbirth (cate-
gorised as years: 1990–1995, 1996–2001, 2002–2007, and
2008–2013). We also extracted other maternal factors,
including most recent body mass index (BMI) measure-
ment before pregnancy (classified as normal, underweight,
overweight, and obese, according to World Health Organi-
zation classification),21 most recent smoking status before
delivery, and socio-economic status, as measured by quin-
tiles of the Townsend Index of Material Deprivation. In
addition, women with periconceptional high-dose folic acid
supplementation were defined as those with at least one
prescription of 5 mg folic acid within the 12 weeks before
conception or in the first trimester of pregnancy. Women
with other autoimmune disorders including type–1 diabe-
tes, rheumatoid arthritis, and thyroid disorder were also
identified, as according to previous research these diagnoses
may be potential confounding factors.17
Statistical analyses
Absolute risks (per 10 000 live births) of any major CA and
14 system-specific groups were calculated for children of
mothers with and without CD separately. Logistic regression
was used to estimate odds ratios (ORs) with 95% confidence
intervals (95% CIs) for any major CA, and 14 system-spe-
cific groups where data were available. We also stratified the
analyses for children of mothers with diagnosed and undiag-
nosed CD separately, and compared the major CA risk with
that in mothers without CD. The generalised estimating
equation approach with exchangeable correlation structure
was applied to take account of potential clustering between
children born to the same woman in consecutive pregnan-
cies. We adjusted our analysis for maternal age, year of
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childbirth, BMI, smoking status, socio-economic status, per-
iconceptional high-dose folic acid supplementation, and
maternal autoimmune disorders.
Sensitivity analyses
We undertook three additional analyses to ensure the
robustness of the study results. Firstly, to increase the spec-
ificity of our CD definition, we repeated our analyses by
restricting the group of mothers with CD to those who had
received a gluten-free prescription. Secondly, a woman
whose first recorded CD diagnosis was in the early postpar-
tum period may have been diagnosed before pregnancy; we
thus repeated our analyses reclassifying mothers who had
their diagnosis recorded within the first 3 months following
childbirth as having diagnosed CD (rather than undiag-
nosed). Thirdly, to assess whether findings changed for
children with only isolated major CAs, we excluded chil-
dren with a chromosomal anomaly or with more than one
major CA. We repeated the main analysis and the first two
sensitivity analyses for children with isolated major CA
only.
All analyses were carried out using STATA SE 11.0 (Stata
Corp., College Station, TX, USA).
Results
Basic characteristics
We identified 562 332 pregnancies resulting in liveborn
singletons, of which 1880 (0.3%) were in women with CD
either diagnosed before childbirth (909 with diagnosed CD)
or after childbirth (971 with undiagnosed CD) (Table 1).
Mothers with CD were slightly older, less likely to be from
socio-economically deprived areas, and were less likely to
be overweight, obese, or smokers, than mothers without
Table 1. Maternal characteristics (n = 562 332)
Without CD With CD Diagnosed CD Undiagnosed CD
n = 560 452 n = 1880 n = 909 n = 971
n % n % n % n %
Maternal age, years
Median, interquartile range 29 25–33 31 27–34 31 27–35 30 27–33
Year of childbirth
1990–1995 101 824 18.16 400 21.28 105 11.55 295 30.38
1996–2001 143 103 25.52 519 27.61 184 20.35 334 34.40
2002–2007 169 156 30.16 574 30.53 303 33.33 271 27.91
2008–2013 146 369 26.10 387 20.59 316 34.76 71 7.31
Body mass index (kg/m2)
Normal (18.5–24.9) 228 561 40.78 839 44.63 437 48.07 402 41.40
Underweight (<18.5) 16 933 3.02 98 5.21 55 6.05 43 4.43
Overweight (25–29.9) 91 389 16.31 245 13.03 142 15.62 103 10.61
Obese (≥30) 53 211 9.49 114 6.06 55 6.05 59 6.08
Missing 170 358 30.40 584 31.06 220 24.20 364 37.49
Smoking status
Non-smokers 326 535 58.26 1145 60.90 613 67.44 532 54.79
Smokers 83 212 14.85 221 11.76 122 13.42 99 10.20
Missing 150 705 26.89 514 27.34 174 19.14 340 35.02
Townsend deprivation index
1 (least deprived) 130 043 23.20 539 28.67 246 27.06 293 30.18
2 106 566 19.01 364 19.36 185 20.35 179 18.43
3 109 863 19.60 375 19.95 182 20.02 193 19.88
4 102 691 18.32 297 15.80 133 14.63 164 16.89
5 (most deprived) 75 899 13.54 199 10.59 108 11.88 91 9.37
Missing 35 390 6.31 106 5.64 55 6.05 51 5.25
Periconceptional high-dose
folic acid supplementation*
21 428 3.82 145 7.71 94 10.34 51 5.25
Type–1 diabetes 2767 0.49 54 2.87 24 2.64 30 3.09
Rheumatoid arthritis 4626 0.83 18 0.96 4 0.44 14 1.44
Thyroid disorder 12 142 2.17 99 5.27 69 7.59 30 3.09
*With at least one prescription of 5 mg of folic acid in the 12 weeks before conception or in the first trimester of pregnancy.
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CD, yet they were more likely to have type–1 diabetes or
thyroid disorder (Table 1). A higher proportion of mothers
received 5 mg folic acid supplementation around early
pregnancy if they had CD than if not (7.7% versus 3.8%),
especially in mothers with diagnosed CD (10.3%). Com-
pared with mothers with diagnosed CD, mothers with
undiagnosed CD had more missing data on BMI and
smoking status, and they had more pregnancies in the ini-
tial years of follow-up (Table 1).
Risks of major CA associated with CD overall
The risk of children with a major CA was broadly similar
between mothers with CD (293 per 10 000 liveborn single-
tons) and without CD (282 per 10 000 liveborn singletons)
(Table 2). This corresponds to an OR of 1.04 (95% CI
0.78–1.37), which decreased slightly to 0.98 (95% CI 0.74–
1.30) after adjustment for potential confounding factors
(Table 3). The risks of most system-specific anomalies such
as anomalies of the heart and genital system and cleft lip,
with or without cleft palate, were also similar between chil-
dren of mothers with and without CD (Tables 2 and 3).
In children born to women with CD, five of them had ner-
vous system anomalies and only one had an NTD. The abso-
lute risks of nervous system anomalies were 27 per 10 000
liveborn singletons and 16 per 10 000 liveborn singletons in
children of mothers with and without CD, respectively
(adjusted OR 1.60, 95% CI 0.57–4.48; Tables 2 and 3).
Risks of major CA associated with diagnosed and
undiagnosed CD separately
The risk of major CA was 231 per 10 000 liveborn single-
tons in the diagnosed CD group, but 350 per 10 000 live-
born singletons in the undiagnosed CD group (Table 4).
Compared with children of mothers without CD, the
adjusted ORs were 0.80 (95% CI 0.52–1.23) and 1.15
(95% CI 0.80–1.65), respectively (Table 4). For system-spe-
cific anomalies, most adjusted ORs included a null risk in
both diagnosed and undiagnosed CD, except that children
born to women with undiagnosed CD in pregnancy had a
statistically significantly increased risk of anomalies of the
nervous system (adjusted OR 2.98, 95% CI 1.06–8.33, com-
pared with children of mothers without CD).
The absolute risk of nervous system anomalies in the
undiagnosed group was 51 per 10 000 liveborn singletons.
This result was based on only five exposed cases (three with
microcephaly, one with hydrocephalus, and one with spina
bifida). The adjusted OR for NTDs, based on one case with
spina bifida, was 4.16 (95% CI 0.59–29.45). There was no
specific pattern in the maternal sociodemographic and life-
style characteristics of the five exposed cases.
Table S7 shows the relative risks of major CAs in chil-
dren of mothers with CD after restricting the data to
mothers with a gluten-free prescription (76.4% of the origi-
nal CD population). Although the overall number of moth-
ers with CD decreased (443 children of mothers with CD
Table 2. Absolute risks (per 10 000 liveborn singletons) of major congenital anomalies in children born to women with and without coeliac
disease in pregnancy (n = 562 332)
Total population Without CD With CD
n = 562 332 n = 560 452 n = 1880
n n/10 000 n n/10 000 n n/10 000
Major congenital anomalies overall 15 850 282 15 795 282 55 293
Heart 4516 80 4501 80 15 80
Limb 3025 54 3009 54 16 85
Genital system 2291 41 2283 41 8 43
Urinary system 1470 26 1464 26 6 32
Chromosomal 1069 19 1067 19 2 11
Orofacial cleft 783 14 780 14 3 16
Nervous system 880 16 875 16 5 27
Neural tube defects* 136 2 135 2 1 5
Musculoskeletal system 778 14 776 14 2 11
Digestive system 593 11 593 11 0 –
Eye 620 11 620 11 0 –
Other malformations** 581 10 578 10 3 16
Respiratory system 368 7 368 7 0 –
Ear, face, and neck 145 3 145 3 0 –
Abdominal wall 132 2 132 2 0 –
*Including anencephalus, encephalocoele, and spina bifida.
**E.g. asplenia, situs inversus, and skin disorders.
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but without a gluten-free prescription were excluded), the
adjusted OR remained similar to the main analyses
(aOR 1.00, 95% CI 0.73–1.37) and all other 95% CIs
included unity (Table S7).
Table S8 shows the relative risks of major CAs after re-
classifying mothers whose CD diagnosis was first recorded
in the 3 months following childbirth as having diagnosed
CD, rather than undiagnosed CD. Compared with the
results from the main analyses, the adjusted ORs for the
diagnosed and undiagnosed groups remained almost
unchanged, and we again found a slightly increased risk of
nervous system anomalies in the undiagnosed group
(aOR 2.99, 95% CI 1.07–8.37).
There were 1787 children with a chromosomal anomaly
or with more than one major anomaly (11.3% of children
with any major CA). After repeating the analyses in children
with isolated major CA, we found very similar results to the
analyses in children with any major CA (Tables S1–S6).
Discussion
Principal findings
Overall, we found no increased risk of major CA in chil-
dren of mothers with CD, compared with children of
mothers without CD. The major CA risk in children of
mothers with diagnosed CD was similar to the risk in the
general population. Risk estimates for major CA were
slightly higher, although not statistically significant, for
children born to mothers with undiagnosed CD. This was
mainly related to a three-fold statistically significant
increase of nervous system anomalies in children of moth-
ers with undiagnosed CD, although this was derived from
only five exposed cases (one with a NTD).
Strengths and limitations
Our study is among the very few studies to examine the
major CA risk in children of mothers with CD on such a
large scale. Besides the overall major CA risk, we have also
examined the risk for system-specific anomalies. Although
the numbers in some specific anomaly groups are inevita-
bly low (e.g. we have about 60% power to estimate a
three-fold increased risk of nervous system anomalies asso-
ciated with undiagnosed CD, at the 5% significance level,
which decreased considerably to just over 30% after using
the restricted CD definition), our study is the second larg-
est published study thus far. The THIN database used in
this study is broadly representative of the UK population
in terms of demographics and chronic disease prevalence,22
which makes our study findings generalisable to the rest of
the UK and likely to wider afield. As data are routinely col-
lected through the general practice, exposures and covari-
ates are prospectively recorded prior to diagnoses of major
CA, minimising recall bias.
There could of course be some misclassification in terms
of maternal CD in our study. It is likely that some mothers
without CD in our study had undiagnosed disease through-
out the whole study period. This is likely to have biased
our results, if at all, towards the null, i.e. of no increase in
risk of major CA. Population screening, however, indicates
that only up to 1% of people with no detected symptoms
are seropositive for CD,2 so the degree of misclassification
is likely to be very low. Another potential limitation of
using large routinely collected data, such as data from
THIN, is that we were unable to validate the diagnostic
data for each patient; however, when we increased the
specificity of our exposure definition by restricting our
analysis to only women with a gluten-free prescription, we
found similar results to the main analyses.
We assumed that once women were diagnosed with CD
they would take a gluten-free diet and thus be reasonably
well protected from further damage of the small bowel.
This assumption may not always be true; however, com-
plete non-compliance of gluten-free diet among those with
CD is uncommon.23 It is possible that women who we
defined as having undiagnosed CD in pregnancy in this
study actually had existing CD before or during pregnancy,
but this was not recorded until the early postpartum period
when there may be increased GP contact related to their
newly born child; however, when we reclassified mothers
Table 3. Odds ratios for major congenital anomalies in relation to
maternal coeliac disease
Unadjusted OR Adjusted OR*
OR 95% CI OR 95% CI
Major congenital
anomalies overall
1.04 0.78–1.37 0.98 0.74–1.30
Heart 1.00 0.60–1.66 0.92 0.55–1.53
Limb 1.59 0.97–2.60 1.49 0.91–2.44
Genital system 1.04 0.52–2.08 0.99 0.49–1.99
Urinary system 1.23 0.55–2.75 1.15 0.52–2.58
Chromosomal 0.56 0.14–2.26 0.52 0.13–2.07
Orofacial cleft 1.14 0.37–3.55 1.15 0.37–3.55
Nervous system 1.66 0.59–4.64 1.60 0.57–4.48
Neural tube defects** 2.21 0.31–15.79 2.23 0.32–15.47
Musculoskeletal system 0.76 0.19–3.06 0.75 0.19–3.01
Other malformations*** 1.53 0.36–6.51 1.47 0.34–6.28
Comparison group includes children of women without CD; system-
specific anomalies with no exposed cases were not presented in the
table.
*Adjusted for maternal age, year of childbirth, body mass index,
smoking, socio-economic status, periconceptional folic acid
supplementation, type–1 diabetes, rheumatoid arthritis, and thyroid
disorders.
**Including anencephalus, encephalocele, and spina bifida.
***E.g. asplenia, situs inversus, and skin disorders.
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with CD in the first 3 months after childbirth as having
diagnosed CD rather than undiagnosed CD, we found very
similar results to the main analyses.
Among the children, we had a median of 4 years of fol-
low-up data after birth and we included major CAs diag-
nosed up to age 20 years, where available, so we expect to
have captured these for live births as completely if not
more completely than registry data.24 We have only
assessed the risks for major anomalies, as these have been
validated against written primary care records,25 and the
prevalence estimates across all system-specific groups and
for specific anomaly diagnoses have been shown to be com-
parable with those reported in UK registers of the Euro-
pean Surveillance of Congenital Anomalies network.24 As
nearly 90% of children with any major CA had only an iso-
lated anomaly, and as the aetiology between isolated and
multiple anomalies can differ, we also conducted a sensitiv-
ity analysis excluding children with a chromosomal anom-
aly or children with more than one anomaly, and found
very similar results to the main analyses. Moreover, as still-
born children are not registered with a general practice we
only included liveborn children, as is the case in most pre-
vious studies. Stillbirth occurs in approximately 0.6% of
births in developed countries,26 and CAs account for only
8–14% of stillbirths,27,28 so the effect of excluding them on
our estimates should be minimal. We were also unable to
ascertain CAs in pregnancies ending in miscarriage or ter-
mination. It is likely that a considerable proportion of
pregnancies where the fetus has a severe major CA, espe-
cially an NTD, would end in spontaneous or induced abor-
tion. There are no accurate data sources to ascertain CAs
in these cases, as spontaneous abortion is likely to occur in
early pregnancy when many women may not know that
they are pregnant, and autopsy information on later losses
is rarely ascertained. This is similar for induced abortion
(or medical termination), as most happen in early preg-
nancy. The UK registry ascertainment of major CAs among
medically terminated pregnancies varies regionally,29 and
national abortion statistics estimate that only 1% are for
major CAs.30 Nevertheless, this would only lead us to
underestimate a potentially true teratogenic effect of CD,
and no studies thus far have been able to overcome this
methodological problem.
We have adjusted our results for maternal sociodemo-
graphic factors, folic acid supplementation, and comorbidi-
ties. To the best of our knowledge, no population-based
studies have assessed intake of folic acid in the risks of CAs
associated with CD. Although both 0.4- and 5-mg tablets of
Table 4. Absolute risks and adjusted odds ratios of major congenital anomalies in children of mothers with undiagnosed and diagnosed coeliac
disease
Diagnosed CD Undiagnosed CD
n = 909 n = 971
n n/10 000 aOR* 95% CI n n/10 000 aOR* 95% CI
Major congenital anomalies overall 21 231 0.80 0.52–1.24 34 350 1.14 0.79–1.64
Heart 7 77 0.89 0.42–1.87 8 82 0.95 0.48–1.91
Limb 7 77 1.44 0.69–3.04 9 93 1.53 0.79–2.94
Genital system 1 11 0.26 0.04–1.83 7 72 1.66 0.79–3.50
Urinary system 4 44 1.60 0.60–4.29 2 21 0.74 0.18–2.98
Chromosomal 2 22 1.06 0.26–4.24 0 – –
Orofacial cleft 2 22 1.67 0.42–6.67 1 10 0.70 0.10–5.01
Nervous system 0 – – 5 51 2.98 1.06–8.33
Neural tube defects** 0 – – 1 10 4.16 0.59–29.45
Musculoskeletal system 1 11 0.89 0.13–6.38 1 10 0.62 0.09–4.41
Digestive system 0 – – 0 – –
Eye 0 – – 0 – –
Other malformations*** 0 – – 3 31 2.50 0.58–10.73
Respiratory system 0 – – 0 – –
Ear, face, and neck 0 – – 0 – –
Abdominal wall 0 – – 0 – –
Comparison group includes children of women without CD; empty cells indicated insufficient numbers.
*Odds ratio adjusted for maternal age, body mass index, smoking, socio-economic status, periconceptional folic acid supplementation, type–1
diabetes, rheumatoid arthritis, and thyroid disorders.
**Including anencephalus, encephalocele, and spina bifida.
***E.g. asplenia, situs inversus, and skin disorders.
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folic acid are sold in the UK market, 5-mg tablets can only
be issued with a prescription from a health care profes-
sional.31 In the UK chronic conditions like CD are normally
managed in primary care. Therefore, such high-dose folic
acid prescriptions should be largely captured in these data.
Low-dose folic acid is widely available as an over-the-counter
drug, however, and can be purchased directly from pharma-
cies. We have no information on folic acid intake through
diet, although the level of such intake is likely to be minimal
(e.g. about 0.2 mg/day according to the UK National Diet &
Nutrition Survey),32 and previous studies have shown folic
acid supplementation to be effective in reducing risks of
NTDs at a dosage of 0.36–4.00 mg/day.33–38
Finally, we acknowledge that mothers with undiagnosed
CD had more missing values on BMI and smoking status
than mothers with diagnosed CD. We also observed lower
proportions of mothers with undiagnosed CD in more
recent years, compared with those with diagnosed CD.
These represented pregnancies in the undiagnosed group
occurring earlier in the data, and vice versa for those with
diagnosed CD. We therefore adjusted for the calendar per-
iod and included missing values as separate categories in
the multivariable analyses. We found the results were
roughly similar between unadjusted and adjusted ORs.
Interpretation in the context of previous literature
A study that linked biopsy reports to various national reg-
isters from Sweden was published recently,17 and showed
that the risk of overall CAs was slightly higher in children
of mothers with undiagnosed CD than in children of
mothers without CD (aOR 1.16, 95% CI 1.04–1.29, after
adjustment for various maternal sociodemographic factors
and comorbidities). Although the Swedish study included a
much larger study population than ours, with over 11 000
children of mothers with CD, the similar effect found
between our study and theirs is reassuring. The Swedish
study also found a small increase in the risk of heart anom-
alies in the undiagnosed group (OR 1.32, 95% CI 1.06–
1.66), but no increase in the risk of NTDs, limb anomalies,
or orofacial clefts. The association with heart anomalies,
however, disappeared after the authors restricted the analy-
ses to children born after 1982, indicating that there were
some unmeasured confounding effects. Similar to our
study, a previous UK study using primary care data also
identified one child with an NTD in the CD group; how-
ever, this study did not present results for other CAs.8
Other previous studies were small clinical studies, with only
one or two exposed cases, and with screening for CD in
mothers whose children had various CAs, so they are not
directly comparable with our study.13–16
In terms of the possible mechanisms that could increase
the likelihood of major CAs in children born to women
with CD, previous research has shown that compared with
healthy controls red cell and serum folate levels are lower
in patients with untreated CD, but not in patients with
recovered villous atrophy.39 Folate deficiency can impair
the synthesis and replication of deoxyribonucleic acid
(DNA), especially when increased blood volume and red
cell mass and the growing fetus in pregnancy impose addi-
tional demands for folate on the mother.40,41 This may
result in disruption of the growth and differentiation of
neural crest cells in early pregnancy, when folate is most
essential for the fetus.41 Mothers with dysregulated folate
metabolism therefore have the potential for experiencing
severe consequences in pregnancy, such as having an
increased risk of NTDs in their offspring compared with
the general population.41,42 Previous clinical trials have
shown statistically significant decreases of NTDs, heart, and
other CAs in children of mothers taking periconceptional
folic acid supplementation, compared with children of
mothers without folic acid supplementation.33–36,43,44 The
statistically significant increase of nervous system anoma-
lies, although not specifically NTDs, found for mothers
with undiagnosed CD in our study could therefore be
explained by such mechanisms; however, we acknowledge
that this could be a chance finding because of the number
of comparisons we have made.
Conclusion
There was no statistically significant difference in risk of
having children with major CA between women with CD
and without CD. Although we found a small increased risk
of nervous system anomalies in women with undiagnosed
CD compared with the general population, this was based
on a very small number of exposed cases, and should be
regarded cautiously. For women who have been diagnosed
with CD, these findings are reassuring and will help doctors
and other health care workers to advise women with CD
that their risks are similar to those of other women.
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